Comparative Pharmacology
Head-to-head clinical analysis: JENTADUETO XR versus SITAGLIPTIN METFORMIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JENTADUETO XR versus SITAGLIPTIN METFORMIN HYDROCHLORIDE.
JENTADUETO XR vs SITAGLIPTIN; METFORMIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
JENTADUETO XR combines linagliptin, a DPP-4 inhibitor that increases incretin levels (GLP-1, GIP) leading to glucose-dependent insulin secretion and decreased glucagon release, and metformin, an AMPK activator that decreases hepatic gluconeogenesis, reduces intestinal glucose absorption, and improves insulin sensitivity.
Sitagliptin is a DPP-4 inhibitor that increases incretin levels (GLP-1, GIP), enhancing glucose-dependent insulin secretion and reducing glucagon secretion. Metformin is a biguanide that decreases hepatic glucose production, decreases intestinal glucose absorption, and improves insulin sensitivity via AMP-kinase activation.
The usual starting dose of JENTADUETO XR (empagliflozin/metformin extended-release) is 5 mg/1000 mg orally once daily with the evening meal. Dose can be increased to a maximum of 12.5 mg/2000 mg once daily based on glycemic control and tolerability.
1 tablet orally twice daily; each tablet contains sitagliptin 50 mg and metformin hydrochloride 500 mg, 850 mg, or 1000 mg; maximum dose: sitagliptin 100 mg/day, metformin 2000 mg/day.
None Documented
None Documented
Linagliptin: 12 h (terminal, steady-state) with once-daily dosing providing sustained DPP-4 inhibition. Metformin: 6.2 h (terminal elimination) in patients with normal renal function; prolonged in renal impairment, contraindicated if eGFR < 30 mL/min/1.73 m².
Sitagliptin: terminal half-life 12.4 hours (healthy), prolonged in renal impairment (up to 28–39 hours in severe impairment). Metformin: terminal half-life 4–8.7 hours (healthy), prolonged in renal impairment (up to 17.6 hours in moderate impairment).
Linagliptin: ~90% excreted unchanged in feces via enterohepatic recycling, <5% renally eliminated. Metformin: ~90% eliminated unchanged in urine via glomerular filtration and tubular secretion, <10% in feces.
Sitagliptin: 79% excreted unchanged in urine via renal tubular secretion and glomerular filtration; 13% metabolized with 4% excreted in feces. Metformin: 90% excreted unchanged in urine via glomerular filtration and tubular secretion; <5% in feces.
Category C
Category A/B
DPP-4 Inhibitor / Biguanide Combination
DPP-4 Inhibitor